Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Coivas vs LillyDirect Foundayo

Coivas
Graded #194

Lower grade

vs+1
LillyDirect Foundayo
Graded #165

Higher grade

The verdict

LillyDirect Foundayo takes it — 67.2/100 to 66.2/100, but only just.

LillyDirect Foundayo grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Eli Lilly's manufacturer direct-pay channel for Foundayo (orforglipron), the first oral GLP-1 pill for weight loss. Coivas is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueLillyDirect Foundayo +2
70
72
Dose & formulationCoivas +5
64
59
Clinical oversightCoivas +6
84
78
Labs & monitoringCoivas +2
54
52
FulfillmentLillyDirect Foundayo +2
78
80
Contract termsLillyDirect Foundayo +35
20
55
Coivas · left barLillyDirect Foundayo · right bar

The numbers

MetricCoivasLillyDirect Foundayo
WeighScore66.2/10067.2/100
GradeCC
Scorecard rank#194#165
Semaglutide$149/mo (quarterly plan, compounded)Not disclosed
Tirzepatide$229/mo (quarterly plan, compounded)Not disclosed
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
Coivas

Graded #194 · C

Strengths

  • All-inclusive pricing: one price covers doctor consult, prescription, shipping and support
  • Compounded semaglutide from $149/mo and tirzepatide from $229/mo on the quarterly plan
  • Names its clinical provider (Arora Health & Aesthetics, LLC) and cites USP 797 / NABP-accredited pharmacies
  • Available in all 50 states; 24/7 support; HSA/FSA eligible; money-back guarantee
  • Most patients approved in under 2 hours; refund if no provider visit or prescription occurs

Where it loses points

  • Dispensing pharmacies described only by category (503A/503B, NABP-accredited) - not named individually
  • Lower quarterly headline price requires a 3-month commitment; monthly plan costs more ($179/$289)
  • Money-back guarantee has strict adherence/verification conditions and no partial/prorated refunds
  • No brand-name Wegovy/Zepbound/Mounjaro/Ozempic - compounded injectable only; binding NY arbitration
LillyDirect Foundayo

Graded #165 · C

Strengths

  • Cheapest legal path to a brand-name GLP-1 in 2026 ($25/mo with savings card for commercial insurance)
  • Direct from manufacturer — no compounding, no third-party reseller
  • Daily oral pill, no injections, no refrigeration
  • Available in all 50 states

Where it loses points

  • Lower mean weight loss vs Wegovy (14.9%) and Zepbound (20.9%) — labeled-dose 11.1% per Foundayo PI
  • Requires existing prescription from a separate prescriber (LillyDirect does not write the prescription)
  • $25 savings card requires commercial insurance — Medicare and Medicaid not eligible
  • Strict empty-stomach 30-minute window may be hard for some patients to follow

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard